by Alveolus Bio | Jan 5, 2022 | Company News
Birmingham, January 5, 2022 – Alveolus Bio today announced that it will be presenting virtually at the Biotech Showcase™ 2022 conference, which runs during JP Morgan Healthcare Week. With healthcare’s most important event going virtual yet again this year, registered...
by Alveolus Bio | Jan 8, 2021 | Publications
Emerging evidence indicates that early life events can increase the risk for developing chronic obstructive pulmonary disease (COPD). Using an inducible transgenic mouse model for NF-κB activation in the airway epithelium, we found that a brief period of inflammation...
by Alveolus Bio | Feb 21, 2020 | Publications
The pathogenesis of bronchopulmonary dysplasia (BPD) is not well understood. We previously identified differences in the airway microbiome at birth between preterm infants who were BPD predisposed versus those who were BPD resistant. In this study, we attempted to...
by Alveolus Bio | Oct 21, 2016 | Publications
Alterations of pulmonary microbiome have been recognized in multiple respiratory disorders. It is critically important to ascertain if an airway microbiome exists at birth and if so, whether it is associated with subsequent lung disease. Investigators found an...
by Alveolus Bio | Jun 21, 2015 | Publications
The lack of a well-characterized biomarker for the diagnosis of chronic obstructive pulmonary disease (COPD) has increased interest toward finding one, because this would provide potential insight into disease pathogenesis and progression. Since persistent...
Recent Comments